Is Glaxosmithkline expensive at 1630p?

Is Glaxosmithkline expensive at 1630p?

Article image

Glaxosmithkline (LON:GSKis a giant of the Pharmaceuticals industry, with a market cap of £81.2bn and annual sales of c£30bn. The global healthcare company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare.

Recent trading has been positive for the group, with sales up 6% and net income up 51% for the three months to 31 March 2019. However, Glaxosmithkline's share price is on the expensive side, in our view, based on its Value Rank of 45. Let's see why this is.

A closer look at Glaxosmithkline's Value Rank

We can see by using Glaxosmithkline’s StockReport that the group has a:

  • Rolling price to book value of 20.2,
  • Trailing twelve month price to earnings ratio of 13.8
  • Trailing twelve month price to free cashflow of 12.5
  • Rolling dividend yield of 4.91%
  • Trailing twelve-month price to sales ratio of 2.60

This combination of financial traits suggests that Glaxosmithkline stock is toward the more expensive end of the market. Being expensive is not the end of the world, of course - but it does help to have favourable exposures to other factors to justify the share price premium.


What does this mean for potential investors?

Some of the best quality stocks in the market have defensible models that can deliver high levels of shareholder returns over the long term. But there are no guarantees and it's important to do your own research. Indeed, we've identified some areas of concern with GSK that you can find out about here.


About us

Stockopedia helps individual investors make confident, profitable choices in the stock market. Our StockRank and factor investing toolbox unlocks institutional-quality insights into thousands of global stocks. Voted “Best Investment Research Tools” and “Best Research Service” at the 2021 UK Investor Magazine awards.

GSK's StockRank™

NeutralConservative

GSK's StockRank™

With a StockRank of 85, GSK is more attractive than 85% of the 7,463 stocks we cover in Europe, according to our proprietary ranking system.

See the full StockReport

Absolutely Perfect

"Trialed multiple other platforms - this is by far my favourite. Other platforms do not even have half the stuff that you can find on Stockopedia. Love it!"

As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.